# The Constitutive Activity of Spinal 5-HT6 Receptors
Contributes to Diabetic Neuropathic Pain in Rats

Nazarine Mokhtar, Marcin Drop, Florian Jacquot, Sylvain Lamoine, Eric Chapuy, Laetitia Prival, Youssef Aissouni, Vittorio Canale, Frédéric Lamaty, Pawel Zajdel, et al.

<figure><img src="image_1.png" /></figure>

► To cite this version:

Nazarine Mokhtar, Marcin Drop, Florian Jacquot, Sylvain Lamoine, Eric Chapuy, et al. The Constitutive Activity of Spinal 5-HT6 Receptors Contributes to Diabetic Neuropathic Pain in Rats. Biomolecules, 2023, Recent Advances on 5-HT6 Receptors, 13 (2), pp.364. 10.3390/biom13020364. hal-04094286

HAL Id: hal-04094286

https://uca.hal.science/hal-04094286

Submitted on 5 Dec 2023

HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d'enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.

<figure><img src="image_2.png" /></figure>
<figure><img src="image_3.png" /></figure>

biomolecules

IMPACT FACTOR

6.064

Indexed in:

PubMed

Article

# The Constitutive Activity of Spinal 5-HT₆ Receptors Contributes to Diabetic Neuropathic Pain in Rats

Nazarine Mokhtar, Marcin Drop, Florian Jacquot, Sylvain Lamoine, Eric Chapuy, Laetitia Prival, Youssef Aissouni, Vittorio Canale, Frédéric Lamaty, Paweł Zajdel et al.

Special Issue

Recent Advances on 5-HT6 Receptors

Edited by

Prof. Dr. Philippe De Deurwaerdere, Prof. Dr. Abdeslam Chagraoui and

Dr. Séverine Chaumont-Dubel

<figure><img src="image_4.png" /></figure>
Article

# The Constitutive Activity of Spinal 5-HT<sub>6</sub> Receptors Contributes to Diabetic Neuropathic Pain in Rats

Nazarine Mokhtar<sup>1</sup>, Marcin Drop<sup>2,3</sup>, Florian Jacquot<sup>1</sup>, Sylvain Lamoine<sup>1</sup>, Eric Chapuy<sup>1</sup>, Laetitia Prival<sup>1</sup>, Youssef Aissouni<sup>1, D</sup>, Vittorio Canale<sup>3, D</sup>, Frédéric Lamaty<sup>2, D</sup>, Paweł Zajdel<sup>3, D</sup>, Philippe Marin<sup>4, D</sup>, Stéphane Doly<sup>1</sup> and Christine Courteix<sup>1,* D</sup>

**Abstract:** Diabetic neuropathy is often associated with chronic pain. Serotonin type 6 (5-HT<sub>6</sub>) receptor ligands, particularly inverse agonists, have strong analgesic potential and may be new candidates for treating diabetic neuropathic pain and associated co-morbid cognitive deficits. The current study addressed the involvement of 5-HT<sub>6</sub> receptor constitutive activity and mTOR signaling in an experimental model of diabetic neuropathic pain induced by streptozocin (STZ) injection in the rat. Here, we show that mechanical hyperalgesia and associated cognitive deficits are suppressed by the administration of 5-HT<sub>6</sub> receptor inverse agonists or rapamycin. The 5-HT<sub>6</sub> receptor ligands also reduced tactile allodynia in traumatic and toxic neuropathic pain induced by spinal nerve ligation and oxaliplatin injection. Furthermore, both painful and co-morbid cognitive symptoms in diabetic rats are reduced by intrathecal delivery of a cell-penetrating peptide that disrupts 5-HT<sub>6</sub> receptor-mTOR physical interaction. These findings demonstrate the deleterious influence of the constitutive activity of spinal 5-HT<sub>6</sub> receptors upon painful and cognitive symptoms in diabetic neuropathic pains of different etiologies. They suggest that targeting the constitutive activity of 5-HT<sub>6</sub> receptors with inverse agonists or disrupting the 5-HT<sub>6</sub> receptor-mTOR interaction might be valuable strategies for the alleviation of diabetic neuropathic pain and cognitive co-morbidities.

**Keywords:** neuropathic pain; diabetes; 5-HT<sub>6</sub> receptor; constitutive activity; inverse agonism; mTOR; Streptozocin

## 1. Introduction

Diabetic neuropathy (DN) represents a major complication of type 1 and type 2 diabetes mellitus (T1DM, T2DM). It is estimated to affect 50-70% of the 537 million people with diabetes worldwide [1] and is considered the most common neuropathy in the western world [2]. Clinical manifestations of diabetic neuropathy are various and mainly include diabetic distal symmetric sensory or sensorimotor neuropathy developing as a « dying-back » neuropathy. It affects the most distal extremities first then extends to the trunk and occasionally to the upper limbs corresponding to a « glove and stocking » distribution [3].

Painful diabetic neuropathy (pDN) is defined as « pain as a direct consequence of abnormalities in the peripheral somatosensory system in people with diabetes » [4,5]. In 2013, in France, patients suffering from chronic pain with neuropathic characteristics represented 20.3% of diabetic patients; this prevalence was found to be similar between patients with T1DM (14.7%) and T2DM (24.7%) [6] and tends to increase with longer duration of diabetes. Clinical signs of pDN include evoked and spontaneous pain and sensory loss. Painful DN is often associated with symptoms of anxiety and depression [7], sleep disorders [8], cognitive deficits [9], and decreased quality of life [6,10,11].

<figure><img src="image_5.png" /></figure>

### check for updates

**Citation:** Mokhtar, N.; Drop, M.; Jacquot, F.; Lamoine, S.; Chapuy, E.; Prival, L.; Aissouni, Y.; Canale, V.; Lamaty, F.; Zajdel, P.; et al. The Constitutive Activity of Spinal 5-HT<sub>6</sub> Receptors Contributes to Diabetic Neuropathic Pain in Rats. *Biomolecules* **2023**, *13*, 364. https://doi.org/10.3390/biom13020364

Academic Editor: Omar Cauli

Received: 29 December 2022

Revised: 30 January 2023

Accepted: 13 February 2023

Published: 15 February 2023

<figure><img src="image_6.png" /></figure>

**Copyright:** © 2023 by the authors.
Licensee MDPI, Basel, Switzerland.
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

<footnote n="1"><sup>1</sup> Université Clermont Auvergne, INSERM, NEURO-DOL, 63000 Clermont-Ferrand, France</footnote>

<footnote n="2"><sup>2</sup> IBMM, Université de Montpellier, CNRS, INSERM, 34094 Montpellier, France</footnote>

<footnote n="3"><sup>3</sup> Faculty of Pharmacy, Jagiellonian University Medical College, 9 Medyczna Str., 30-688 Kraków, Poland</footnote>

<footnote n="4"><sup>4</sup> Institut de Génomique Fonctionnelle, Université de Montpellier, CNRS, INSERM, 34094 Montpellier, France</footnote>

<footnote>* Correspondence: christine.courteix@uca.fr; Tel.: +33-473178016</footnote>
International guidelines recommend amitriptyline (tricyclic antidepressant), duloxetine (serotonin and noradrenaline reuptake inhibitor), and pregabalin or gabapentin (alpha2-delta calcium channel ligands) as first-line agents for symptomatic analgesic therapy in patients with diabetic peripheral neuropathic pain. Nevertheless, due to its severity and chronicity, neuropathic pain is difficult to manage, and first-line treatments have unsatisfying efficacy, as attested by the number of patients needed to treat (NNT) for 50% pain relief being above 3 [12]. Until now, there has been no recommendation regarding which first-line agent to use first and which alternative to use when pain relief is suboptimal. Of interest, combination treatments such as amitriptyline supplemented with pregabalin and duloxetine supplemented with pregabalin, led to improved pain relief in patients with insufficient pain control and could be new options in the management of diabetic peripheral neuropathic pain [13]. The difficulties in treating diabetic neuropathic pain remain in the complexity of pathophysiological mechanisms involved in diabetic neuropathy and in the heterogeneity of the patient's response to analgesics [14].

The serotonin type 6 (5-HT<sub>6</sub>) receptor is expressed in the dorsal spinal cord in interneurons receiving non-painful mechanical inputs [15]. Through the Gαs protein, the 5-HT<sub>6</sub> receptor is positively coupled to adenyl-cyclase/cyclic adenosine monophosphate (cAMP)/protein kinase A signaling, leading to the production of cAMP and neuron depolarization. In addition to this canonical pathway, the 5-HT<sub>6</sub> receptor was shown to engage the mechanistic target of rapamycin (mTOR) [16] and cyclin-dependent-kinase 5 (Cdk5) pathways [17]. 5-HT<sub>6</sub> receptor, like other serotonin receptors, is also able to be spontaneously active in the absence of endogenous serotonin [18]. Constitutive activity of 5-HT<sub>6</sub> receptors has been reported for recombinant and native receptors [17,19] and in vivo [20,21].

Preclinical studies performed in animal models of neuropathic pain resembling human neuropathic pain with a high translational value have shown that 5-HT<sub>6</sub> receptor ligands have a strong analgesic potential and may be new candidates to treat traumatic and chemotherapy-induced peripheral neuropathy (CIPN) [21,22]. The mechanism of action of such ligands relies on their ability to abolish the constitutive activity, serotonin independent, of 5-HT<sub>6</sub> receptors, abnormally enhanced in these pathological situations. The drugs acting as inverse agonists were shown to inhibit the mechanistic target of rapamycin (mTOR) signaling upon 5-HT<sub>6</sub> receptor dependence in the dorsal horn spinal cord, whereas 5-HT<sub>6</sub> receptor-neutral antagonists failed to inhibit mTOR activity and alleviate neuropathic pain [21]. PZ-1386 and PZ-1179 belong to a class of 2-phenyl-1H-pyrrole-3-carboxamides and behave as inverse agonists of 5-HT<sub>6</sub> receptor with Ki values of 23 nM and 30 nM, respectively [22,23]. Pharmacokinetic studies revealed that both compounds could pass through the blood-brain barrier reaching Cmax in the brain after 30 min (PZ-1386) and 5 min (PZ-1179). In addition to these favorable features, PZ-1386 was shown to reduce tactile allodynia in spinal nerve ligation (SNL)-induced traumatic neuropathic pain [23], and PZ-1179 was shown to exhibit procognitive properties in rats [22].

Since diabetes is a systemic disease impacting numerous metabolic pathways, including mTOR signaling, we hypothesized that targeting the 5-HT<sub>6</sub>-mTOR pathway may have considerable effects on painful diabetic neuropathy. Indeed, it is well established that mTOR signaling plays an important role in glucose homeostasis by regulating pancreatic β-cell function [24] and neuronal functions. The experimental model of streptozocin (STZ)-induced diabetic rats is currently used to study the pathophysiology of diabetic neuropathy; its complications include pain [25,26] and associated co-morbid cognitive deficit [27]. In this model, a decreased expression in the dorsal horn spinal cord of the adaptor protein APPL1, critical for insulin signaling, has been observed. This is accompanied by an increased p-mTOR expression and an exacerbation of hyperalgesia [28], suggesting that mTOR inhibition would be effective in relieving diabetic neuropathic pain. Accordingly, metformin, an indirect AMPK activator, which negatively regulates mTOR activity, was shown to prevent and reverse neuropathic pain in the spared nerve injury model in mice [29]. This effect was associated with decreased microglia activation in dorsal horn spinal cord. Metformin was also shown to attenuate neuropathic pain via AMPK/NF-κB
signaling in dorsal root ganglia of diabetic rats [30]. These data, reporting the beneficial effect of mTOR inhibition in the dorsal horn spinal cord or the dorsal root ganglia, together with our previous observations reporting the anti-allodynic effect of mTOR inhibition in CIPN and traumatic neuropathic pain models [21,22], prompted us to examine whether modulating 5-HT<sub>6</sub> receptor activity and signaling in the spinal cord (i.e., where the pain signal is highly modulated by central top-down controls), could be effective in painful diabetic neuropathy. For this, we investigated the involvement of 5-HT<sub>6</sub> receptor constitutive activity and mTOR signaling in diabetic neuropathic pain and co-morbid cognitive symptoms induced by STZ administration in the rat using newly developed 5-HT<sub>6</sub> receptor inverse agonists, PZ-1386, and PZ-1179, two 2-phenyl-1H-pyrrole-3-carboxamide derivatives of PZ-1388. In STZ diabetic rats, we show that blocking the constitutive activity of spinal 5-HT<sub>6</sub> receptors reduces mechanical hyperalgesia and co-morbid cognitive symptoms. The 5-HT<sub>6</sub> receptor ligands also reduced tactile allodynia in traumatic and toxic neuropathic pain induced by SNL and oxaliplatin (OXA) injection. mTOR inhibition, as well as disruption of 5-HT<sub>6</sub>-mTOR interaction, also attenuated diabetic neuropathic pain. These results suggest that STZ-induced diabetes causes dysregulation of the 5-HT<sub>6</sub> signaling pathway and that inverse agonists could be a reliable strategy to alleviate diabetic neuropathic pain and associated cognitive co-morbidity.

**2. Materials and Methods**

**2.1. Ethics**

All the experiments described here on animals were conducted in accordance with the ARRIVE guidelines [31] and were reviewed and approved by the local Animal Experiment Ethics Committee of Auvergne (CEMEA) and by the French Ministry of Higher Education, Research and Innovation (authorizations *n*° 5175 (STZ rats), *n*° 17573 (SNL rats) and *n*° 24498 (OXA rats)). All efforts were made to minimize the suffering and the number of animals used.

**2.2. Animals and Models of Neuropathic Pain**

Sprague-Dawley male rats (initial weight 200-250 g) were purchased from Janvier Labs (Le Genest-Saint-Isle, France) one week before starting the experiment. Rats were housed, three (diabetic rats) or four (healthy rats) in a cage under standard laboratory conditions with a 12 h light/dark cycle, stable temperature (22 ± 1 °C), controlled humidity (55 ± 10%) and were given food and water ad libitum. At the end of the experiments, animals not collected for biochemical studies were euthanized by progressive carbon dioxide inhalation (10-30 %/min).

The previously described streptozocin (STZ)-induced neuropathic pain model was used [26]. Diabetes was induced by a single intraperitoneal (i.p.) injection of STZ (75 mg kg⁻¹, Sigma-Aldrich, St-Quentin-Fallavier, France) dissolved in water for injections. An equal volume of water for injections was administrated (i.p.) to healthy rats to serve as a control group. Diabetes was confirmed one week after injection by measuring blood glucose levels in the tail vein with the Accu-Chek® Performa glucometer (Roche, France). At this stage, diabetic rats, i.e., animals with blood glucose > 14 mM, received a subcutaneous (s.c.) injection of insulin (LANTUS®, Sanofi-Aventis, Paris, France, 2 I.U./injection every other day) to ensure a good clinical condition during the entire experiment.

The spinal nerve ligation (SNL) model was performed as previously described [32]. Briefly, under xylazine 2%/ketamine (75 mg/kg i.p) anesthesia, left spinal nerve L5 was tightly ligated (4-0 silk suture, Mersilk, Ethicon LLC Johnson & Johnson, San Lorenzo, Puerto Rico). After surgery, animals were treated with a non-steroidal anti-inflammatory drug (Meloxicam, 2 mg/kg s.c., one injection per day for 2 days). The animals were allowed to recover and were monitored routinely to ensure good health. Signs of disability and distress were absent, and animals did not develop post-operative sensory loss or motor deficit as a consequence of surgery.
The chemotherapy-induced peripheral neuropathy (CIPN) model was induced by a
single i.p. injection of oxaliplatin (OXA, 6 mg/kg) dissolved in a 5% glucose solution [33].

2.3. *Behavioral Tests*

Paw pressure test. Mechanical hyperalgesia to paw pressure was assessed using the Ugo Basile analgesia meter (Bioseb®, Vitrolles, France) [34]. The test consists of the application of an increasing mechanical force exerting important support to the dorsum of the rat's left hind paw until a vocalization or a struggle response occurs (vocalization threshold expressed in arbitrary units, a.u.). The maximum force applied is limited to 450 a.u. to avoid tissue damage. The percentage of pain improvement (% PI) was calculated according to the formulae: % PI = [(Post-drug threshold – Pre-drug threshold) / (Pre-STZ threshold – Pre-drug threshold)] × 100. To investigate the global effects of the drugs, areas under the time-course curves (A.U.C) of the vocalization threshold changes between 0 and 180 min were calculated using the trapezoidal rule.

Von Frey hair test. In SNL and OXA rats, tactile hypersensitivity to light mechanical stimulation was assessed using the von Frey hair test [35]. Each rat was confined in clear Plexiglas boxes placed on an elevated metal mesh floor. Von Frey filaments were applied perpendicularly to the central plantar surface of the hind paw for 5 s in ascending order of force (1.4–26 g). Paw withdrawal or licking was considered a positive response, and the next weaker filament was applied. In case of a negative response (no paw withdrawal or licking), the next stronger filament is applied. This paradigm continued until four measurements were obtained after an initial change of behavior or until four consecutive negative responses or five consecutive positive responses were obtained. The 50% threshold (expressed in grams, g) was calculated using the Up-Down method and Dixon's formulae [36].

Novel object recognition test. Episodic memory was evaluated using the novel object recognition (NOR) test as previously described [37]. Only STZ diabetic rats in which the vocalization threshold was reduced by 25% were included. Rats were habituated to the arena (1-m length, 1-m width) one day before the test. On the test day, rats had a 5-min familiarization session with two identical objects under dim light conditions (30 lux). Rats were transferred back to the home cage for 5 min inter-trial intervals. Then, rats were reintroduced in the arena for training sessions, with one of the original objects replaced by a novel one. The objects were plastic or wood toys (10-cm height, 7-cm length, 7-cm width) and were cleaned with 70% ethanol between sessions. The sequence of presentation and the location of the objects were randomly assigned to each rat. Exploratory behavior was defined as licking or touching the object while sniffing with active vibrissae. Novel object recognition memory was expressed as recognition index (D2 score), defined as the ratio of exploration time of novel object/total objects exploration time.

**2.4. Chemicals**

SB258585 hydrochloride (5-HT<sub>6</sub> receptor antagonist, MW = 523.8 g.mol<sup>-1</sup>) and morphine hydrochloride were purchased from Biotechnle Ltd. (Abingdon, UK).

The 5-HT<sub>6</sub> receptor neutral antagonist IIQ hydrochloride, 4-{[5-methoxy-3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indol-1-yl]sulfonyl}isoquinoline dihydrochloride (MW = 2711.1 g.mol<sup>-1</sup>), was synthetized as previously described [38].

The 5-HT<sub>6</sub> receptor inverse agonists PZ-1388 hydrochloride, 2-(3-fluorophenyl)-1-[(3-chlorophenyl)sulfonyl]-N-(piperidin-4-yl)-1H-pyrrole-3-carboxamide hydrochloride (MW = 534.86 g.mol<sup>-1</sup>), PZ-1386 hydrochloride, 2-(4-fluorophenyl)-1-[(3-chlorophenyl)sulfonyl]-N-(piperidin-4-yl)-1H-pyrrole-3-carboxamide (MW = 534.86 g.mol<sup>-1</sup>) and PZ-1179 hydrochloride, (R)-2-(4-fluorophenyl)-1-[(3-chlorophenyl)sulfonyl]-N-(pyrrolidine-3-yl)-1H-pyrrole-3-carboxamide hydrochloride (MW = 521.33 g.mol<sup>-1</sup>) were synthetized as previously described [21–23].

Tat-VEPE ([NH2]YGRKKRRQRRR-FFVTDSVEPVE[COOH], purity > 98%, MW = 2711.1 g.mol⁻¹), and Tat-SCA ([NH2]YGRKKRRQRRR-TVNEK-VSCA[COOH], purity
> 98%, MW = 2491.2 g.mol⁻¹) peptides were synthetized by Thermo Fisher Scientific (Illkirch-Graffenstaden, France).

## 2.5. Cell Culture and Transfection

The HEK293 cells (ATCC) were cultured in DMEM (Gibco, Thermo Fisher Scientific) containing 10% fetal bovine serum (Gibco, Thermo Fisher Scientific) and 1% penicillin/streptomycin (Sigma) at 37 °C in a 5% CO₂ enriched humidified atmosphere. Transfection (1 µg cDNA) was performed with a Viromer RED kit (Lipocalyx), and the transfected cells were cultured in the same growth medium for 48 h before use. The CMV-5-HT₆-GFP plasmid was provided by Philippe Marin (Institut de Génomique Fonctionnelle, Montpellier, France).

## 2.6. Western Blot Analysis

Cultured cells were solubilized in lysis buffer (75 mM Tris, 2 mM EDTA, 12 mM MgCl₂, 10 mM CHAPS, protease and phosphatase inhibitor mixture EDTA free (Roche cOmplete™) for 2 h at 4 °C. Samples were centrifuged at 11,000 rpm for 20 min at 4 °C. Solubilized proteins were mixed with Laemmli buffer, heated at 95 °C for 5 min. Equal amounts of protein (25 µg) from each sample were resolved onto 10% acrylamide SDS-PAGE gels (TGX Stain-Free™ FastCast™, Biorad) (1.5 h at 90 V) in Tris-Glycine-SDS buffer. Proteins were transferred to nitrocellulose membrane (Trans-Blot® Turbo™, Biorad). Membranes were blocked for 1 h in Tris-buffered saline containing 0.1% Tween-20 and 5% BSA at room temperature. Then membranes were immunoblotted with primary antibodies overnight at 4 °C: anti-total mTOR (1:1000, Cell Signaling Technologies, ref: 2983S), anti-phospho-Ser²⁴⁴⁸-mTOR (1:1000, Cell Signaling Technologies, ref: 2976S), anti-total S6 (1:1000, Cell Signaling Technologies, ref: 2217S), anti-phospho-Ser²⁴⁰/²⁴⁴-S6 (1:1000, Cell Signaling Technologies, ref: 2215S), anti-α-actin (1:1000, Cell Signaling Technologies, ref: 6487S). After several washes, membranes were incubated with anti-rabbit HRP-conjugated secondary antibody (1:5000, Thermo Fisher Scientific) for 1.5 h at room temperature. Immunoreactivity was detected with an enhanced chemiluminescence method using the Chemidoc Touch imaging system (Clarity™ Bio-Rad). Immunoreactive bands were quantified by densitometry using Image Lab 6.1.

## 2.7. Experimental Design

Baseline mechanical sensitivity was determined before STZ injection and again 21 days after. Similarly, baseline tactile threshold was determined before SNL surgery or OXA injection and again 14 days or 3 days after, respectively. At those times, STZ-D, SNL, and OXA rats were considered hyperalgesic (STZ-D rats) or allodynic (SNL- and OXA-rats) if their thresholds were reduced to at least 25%, compared with thresholds measured before the induction of the neuropathy.

Then, for each experimental series, hyperalgesic/allodynic rats were randomly assigned to treatment groups. Thresholds were measured before then every 30 or 60 min for 120 or 180 min after drug injection to follow the effect of the treatments.

Vehicles SB258585, PZ-1388, PZ-1386, and PZ-1179 were injected intraperitoneally (i.p., 5 mL/kg). Rapamycin and Tat-VEPE peptide were administered intrathecally (i.t., 10 µL/rat).

For experiments exploring the involvement of spinal 5-HT₆ receptors in the effect of inverse agonists, the neutral antagonist IIQ was administered i.t. (10 µL/rat) just before i.p. administration of the inverse agonist. Then, thresholds were measured for 120 or 180 min to monitor the effect of the treatments.

For experiments exploring the effect of drugs on cognitive dysfunction, the drugs were administered i.p., and the NOR test was performed with a delay coinciding with the maximal antihyperalgesic effect of the drug.

All the in vivo experiments were performed blind using a parallel group design. Treatments were randomized. Different animals were used in each experiment.
## 2.8. Statistical Analysis

Data were analyzed using the GraphPad Prism software (GraphPad Prism 6 Software). Biochemical and behavioral data were analyzed by a one-way ANOVA followed by Tukey's post-hoc test or a two-way ANOVA, followed by Dunnett's post-hoc test. Results were expressed as mean ± standard error of the mean (S.E.M). The statistical significance was set at 5% (*p* < 0.05). All statistics are detailed in Table 1 and Table S1.

# 3. Results

## 3.1. Diabetes-Induced Mechanical Hyperalgesia

STZ was used to induce pDN. Mechanical hyperalgesia was determined by paw pressure-induced vocalization threshold. As expected [39], STZ-induced diabetes was associated with disturbances of biological and clinical parameters such as hyperglycemia, polydipsia, polyuria, polyphagia, and a halt in weight gain. Ninety-eight percent of STZ-injected rats developed hyperglycemia. Acute mortality occurring within one week of STZ injection was observed in only 2/273 STZ-injected rats. None of the hyperglycemic animals displayed weight loss greater than 10% of their initial weight, motor dysfunction, or prostration. This relatively good health status of diabetic rats is related to insulin administration (every other day). Seventy-nine percent of hyperglycemic rats showed a significant reduction in vocalization threshold 21 days after induction of diabetes (182.8 ± 2.5 a.u. vs. 318.8 ± 1.9 a.u. before STZ), suggesting mechanical hyperalgesia. Twenty-one percent of hyperglycemic rats were not hyperalgesic and were discarded from the study.

## 3.2. Serotonin 6 Receptor Blockade Attenuated Mechanical Hyperalgesia in STZ-Induced Diabetic Rats

To explore the role of constitutive activity of 5-HT₆ receptor in the development of pDN, two well-characterized inverse agonists, PZ-1388 and SB258585, were injected intraperitoneally (i.p.), and mechanical thresholds to paw pressure were measured up to 180 min after injection. Pharmacological inhibition of the 5-HT₆ receptor constitutive activity by PZ-1388 and SB258585 administered at the doses of 5, and 25 µmol/kg significantly attenuated diabetes-induced mechanical hyperalgesia 60–150 or 180 and 30–180 min after injection for PZ-1388 and SB258585, respectively (Figure 1a,b, Table 1). The time course of the antihyperalgesic effect of the drugs showed a maximal effect at 90 min for PZ-1388 and 120 min for SB258585 and corresponded to a pain improvement of 83 ± 21% and 86 ± 9%, respectively. The overall effect assessed by calculation of the area under the time-course curve (A.U.C. 0–180 min) of vocalization threshold changes of the two compounds showed no significant differences between the 5 and 25 µmol doses for each (Figure 1e, Table 1).

<figure><img src="image_7.png" /><figcaption>**Figure 1.** *Cont.*</figcaption></figure>
<figure><img src="image_8.png" /></figure>

<figure><img src="image_9.png" /></figure>

<figure><img src="image_10.png" /></figure>

<figure><img src="image_11.png" /><figcaption>**Figure 1.** Systemic administration of 5-HT<sub>6</sub> receptor inverse agonists reduces diabetic neuropathic pain (paw pressure test). (a) Intraperitoneal administration of PZ-1388, (b) SB258585, (c) PZ-1386, and (d) PZ-1179 (5 and 25 µmol/kg each) but not the vehicle (water for injections) improves mechanical hyperalgesia to paw pressure in STZ diabetic (STZ-D) rats (n = 11–15/group). Vocalization thresholds are expressed as arbitrary units (a.u.). ### *p* < 0.001 vs. values measured before STZ; * *p* < 0.05, ** *p* < 0.01, *** *p* < 0.001 vs. values measured before the drug/vehicle (water) injection (D21 Post-STZ), 2-way ANOVA. (e) Area under the curve (A.U.C.) of vocalization threshold variations in STZ-D and control rats calculated by the trapezoidal rule (in a.u.. min). * *p* < 0.05, ** *p* < 0.01, *** *p* < 0.001, vs. STZ-D Vehicle group; # *p* < 0.05 ### *p* < 0.001 vs. corresponding group, 1-way ANOVA.</figcaption></figure>

<table><caption>**Table 1.** Detailed statistics for figures.</caption><thead><tr><th>Figure</th><th>Analysis</th><th>Statistics (DFn, DFs)</th><th>p Value</th></tr></thead><tbody><tr><td>Figure 1a–d</td><td>2-way RM ANOVA</td><td>F(63, 798) = 12.39</td><td>p < 0.0001</td></tr><tr><td>Figure 1e</td><td>1-way ANOVA</td><td>F(9, 117) = 24.27</td><td>p < 0.0001</td></tr><tr><td>Figure 2b,c</td><td>2-way RM ANOVA</td><td>F(35, 273) = 2.812</td><td>p < 0.0001</td></tr><tr><td>Figure 2d</td><td>1-way ANOVA</td><td>F(5, 39) = 8.252</td><td>p < 0.0001</td></tr><tr><td>Figure 3a</td><td>2-way RM ANOVA</td><td>F(24, 160) = 3.399</td><td>p < 0.0001</td></tr><tr><td>Figure 3b</td><td>1-way ANOVA</td><td>F(3, 20) = 16.11</td><td>p < 0.0001</td></tr><tr><td>Figure 4a</td><td>2-way RM ANOVA</td><td>F(14, 119) = 8.237</td><td>p < 0.0001</td></tr><tr><td>Figure 4b</td><td>1-way ANOVA</td><td>F(2, 17) = 11.23</td><td>p = 0.0008</td></tr><tr><td>Figure 5a</td><td>1-way ANOVA</td><td>F(2, 40) = 6.181</td><td>p = 0.0046</td></tr><tr><td>Figure 5b,c</td><td>1-way ANOVA</td><td>F(3, 27) = 5.497</td><td>p = 0.0044</td></tr></tbody></table>

The newly synthesized inverse agonists PZ-1386 and PZ-1179 significantly reduced mTOR and S6 phosphorylation in HEK cells (Figure S1, Table S1) and, as expected, signifi-
cantly reduced mechanical hyperalgesia in diabetic neuropathic rats (Figure 1c,d, Table 1). This antihyperalgesic effect lasted no more than 120 min for both compounds at 5 µmol and lasted at least 180 min for the dose of 25 µmol. We observed a complete abolition of mechanical hyperalgesia 90 min after administration of the inverse agonist PZ-1179 25 µmol/kg (pain improvement of 109 ± 16%) and a partial improvement after administration of PZ-1386 (pain improvement of 62 ± 8%). Despite the high activity of PZ1179 at 90 min, the overall effect of the two inverse agonists was similar, as shown by the calculation of area under the A.U.C. of vocalization threshold changes (0–180 min) (Figure 1e, Table 1).

Since the anti-allodynic effect of PZ-1388 and SB258585 has been reported to be dependent on spinal 5-HT<sub>6</sub> receptors in SNL and OXA rats [21], we sought their involvement in pDN. To investigate the role of spinal 5-HT<sub>6</sub> receptors in diabetes-induced hyperalgesia, the neutral antagonist IIQ (2 nmol/rat) was injected intrathecally (i.t.) just before i.p. administration of PZ-1179 (25 µmol/kg) or PZ-1386 (25 µmol/kg) or vehicle (water for injections) (Figure 2a) and vocalization thresholds to paw pressure were measured up to 180 min. Consistent with previous findings indicating that neuropathic pain results from a constitutive activity of 5-HT<sub>6</sub> receptors rather than tonic 5-HT<sub>6</sub> receptor activation by endogenous serotonin [21], i.t. administration of the selective neutral antagonist IIQ did not alter the paw pressure-induced vocalization threshold in STZ diabetic rats but completely abolished the antihyperalgesic effect of PZ-1179 (PZ-1179 + IIQ group) (Figure 2b, Table 1). Behavioral results obtained after co-administration of PZ-1386 and IIQ showed an inhibition of the antihyperalgesic effect of PZ-1386 (PZ-1386 + IIQ group) despite a slight elevation of vocalization thresholds to paw pressure (Figure 2c, Table 1). The A.U.C. of the vocalization thresholds changes, which confirms the loss of the antihyperalgesic effect of PZ-1179 and PZ-1386 in the presence of the neutral antagonist (Figure 2d, Table 1). These results indicate that spinal 5-HT<sub>6</sub> receptors' constitutive activity plays a critical role in pDN.

Next, we wondered whether the results obtained on diabetes-induced mechanical hyperalgesia could be extended to traumatic and toxic neuropathic pain in the SNL and CIPN models. PZ-1386 (25 µmol/kg) not only abolished tactile hypersensitivity evoked by von Frey hair stimulation in OXA rats (Figure S2a,b, Table S1) but also exerted a short antinociceptive effect 90 min post-injection (Figure S2f). This brief antinociceptive effect was also observed with PZ-1179 (25 µmol/kg i.p.) 60 min post in SNL and OXA rats (Figure S2c-e, Table S1). Since PZ-1386 and PZ-1179 showed a transient antinociceptive effect in the rat models of traumatic and toxic neuropathic pain, we then explored the effect of both compounds on mechanical nociception (paw pressure test) in healthy rats. PZ-1386 and PZ-1179, given a dose of 10 µmol/kg i.p. (Figure S3a) or 25 µmol/kg i.p. (Figure S3b), failed to increase the paw pressure-induced vocalization threshold (Table S1). Morphine (2 mg/kg, i.p.), a positive control, induced a significant increase in the vocalization threshold (Figure S3a,b, Table S1). Finally, the analgesic effect of both inverse agonists on tactile hypersensitivity (von Frey hair) was completely abolished by simultaneous co-administration of the neutral antagonist IIQ (Figure S2e-g, Table S1). These results suggest that the analgesic effect observed in neuropathic pain models is specific to mechanisms underlying chronic hypersensitivity rather than nociception and depends on the constitutive activity of 5-HT<sub>6</sub> receptors.

### 3.3. Rapamycin and Tat-VEPE Attenuated Hyperalgesia Induced by Diabetes

Inhibiting mTOR activity or interfering with the physical interaction between the C-terminus of the 5-HT<sub>6</sub> receptor and mTOR have been shown to be effective strategies for alleviating traumatic and toxic neuropathic pain [21]. Before exploring the involvement of 5-HT<sub>6</sub> receptor-dependent mTOR signaling in diabetic neuropathic pain, we performed a behavioral experiment with the mTOR inhibitor rapamycin to ensure that the mTOR signaling is engaged. For this purpose, STZ diabetic neuropathic rats were injected i.t. with rapamycin (0.3, 3, and 10 nmol) or vehicle (water for injections, 10 µL/rat) and subjected to the paw pressure test. The results presented in Figure 3 indicate that rapamycin significantly and dose-dependently increases vocalization threshold to paw pressure 30–120 min
(Figure 3a, Table 1). The maximum effect observed at 120 min (297.5 ± 23.4 a.u.) with rapamycin 10 nmol corresponds to a complete reversal of mechanical hyperalgesia (pain improvement of 114 ± 44%). The dose-dependent effect of rapamycin was illustrated by the A.U.C. of changes in the vocalization threshold measured between 0 and 180 min (Figure 3b, Table 1).

<figure><img src="image_12.png" /></figure>

**Figure 2.** 5-HT<sub>6</sub> receptor constitutive activity is involved in mechanical hyperalgesia (paw pressure test) in STZ diabetic rats. (a) Schema illustrating the route of administration of 5-HT<sub>6</sub> receptor ligands in experiment illustrated on panels b–d; (b) Intrathecal administration of IIQ (2 nmol/rat) but not vehicle (water for injections, 10 µL/rat) suppresses the antihyperalgesic effect of PZ-1179 (25 µmol/kg, i.p.) and (c) PZ-1386 (25 µmol/kg, i.p.), respectively (n = 6–9/group). ### *p* < 0.001 vs. values measured before STZ; \* *p* < 0.05, \*\* *p* < 0.01, \*\*\* *p* < 0.001 vs. values measured before drug/vehicle injection (D21 Post-STZ), 2-way ANOVA; (d) Area under the curve (A.U.C.) of vocalization threshold variations in STZ rats calculated by the trapezoidal rule (in a.u. min). \* *p* < 0.05, \*\* *p* < 0.01, vs. Veh + Veh group; \# *p* < 0.05 vs. corresponding group, 1-way ANOVA.
<figure><img src="image_13.png" /></figure>

**Figure 3.** Intrathecal administration of rapamycin suppresses mechanical hyperalgesia (paw pressure test) in STZ diabetic rats. (a) Intrathecal administration of rapamycin (Rapa, 0.3–10 nmol/rat) but not the vehicle (Veh, water for injections) dose-dependently increases the vocalization threshold to paw pressure in STZ rats (n = 6/group). ### p < 0.001 vs. values measured before STZ. \* p < 0.05, \*\* p < 0.01, \*\*\* p < 0.001 vs. values measured before the drug/vehicle injection (D21 Post-STZ), 2-way ANOVA; (b) Area under the curve (A.U.C.) of vocalization threshold variations in STZ rats calculated by the trapezoidal rule (in a.u. min). \* p < 0.05, \*\* p < 0.001, vs. Vehicle group; \# p < 0.05 vs. corresponding group, 1-way ANOVA.

Using a peptidyl mimetic strategy disrupting the physical 5-HT<sub>6</sub>-mTOR interaction, we previously demonstrated that the spinal 5-HT<sub>6</sub> receptor constitutively activates mTOR signaling to contribute to traumatic and toxic neuropathic pain in SNL and OXA rats [21]. The same strategy was used to examine whether inhibiting the physical interaction between the C-terminal domain of the receptor and mTOR would also ameliorate mechanical hyperalgesia to paw pressure in STZ diabetic rats. Intrathecal administration of Tat-VEPE (300 ng/rat i.t.), but not a control peptide (Tat-SCA, 300 ng/rat i.t.), reduced mechanical hyperalgesia 30–120 min after injection in painful STZ diabetic rats (Figure 4a, Table 1). The maximal antihyperalgesic effect (265.7 ± 7.1 a.u.) occurred 60 min after injection, resulting in a 68 ± 8% reversal of mechanical hyperalgesia. The overall antihyperalgesic effect of Tat-VEPE, assessed by the A.U.C. of threshold changes, confirmed the effect of Tat-VEPE compared with the control Tat-SCA peptide (Figure 4b, Table 1).

### 3.4. Effect of 5-HT<sub>6</sub> Receptor Ligands and Tat-VEPE on Co-Morbid Cognitive Symptoms

Pro-cognitive effects of 5-HT<sub>6</sub> receptor ligands have been reported not only in traumatic neuropathic pain models [21] but also in several paradigms of cognitive impairment [22,23,40,41]. Because diabetic rats, like diabetic humans [9], develop cognitive deficits, we next examined whether inverse agonists and peptidyl mimetic strategy would be effective in ameliorating cognitive deficits associated with chronic pain in hyperalgesic diabetic rats. We, therefore, tested the effect of PZ-1179 and PZ-1386 upon episodic memory (NOR task). STZ diabetic rats treated with vehicle failed to discriminate a novel object from the familiar one (Figure 5a, Table 1). Systemic (i.p.) administration of PZ-1386 (25 µmol/kg) but not PZ-1179 (25 µmol/kg) restored the episodic memory deficit elicited by pDN (Figure 5a, Table 1). Reminiscent of the pro-cognitive effect of PZ-1386, intrathecal injection of Tat-VEPE (300 ng/rat) increased novelty discrimination in STZ diabetic rats (Figure 5b, Table 1).
<figure><img src="image_14.png" /></figure>

**Figure 4.** Intrathecal administration of Tat-VEPE attenuates mechanical hyperalgesia (paw pressure test) in STZ diabetic rats. (a) Intrathecal administration of a cell-permeable interfering peptide fused to the transduction domain of the HIV Tat protein (Tat-VEPE, 300 ng/rat) increases the vocalization threshold to paw pressure application in STZ-D rats (n = 6-7/group). ### p < 0.001 vs. values measured before STZ. ** p < 0.01, *** p < 0.001 vs. values measured before the drug/vehicle injection (D21 Post-STZ), 2-way ANOVA; (b) Area under the curve (A.U.C.) of vocalization threshold variations in STZ rats calculated by the trapezoidal rule (in a.u. min). ** p < 0.01 vs. Vehicle group; ## p < 0.01 vs. corresponding group, 1-way ANOVA.

<figure><img src="image_15.png" /></figure>

**Figure 5.** Effect of blocking the constitutive activity of 5-HT<sub>6</sub> receptor or disrupting 5-HT<sub>6</sub>-mTOR interaction on cognitive deficits (novel object recognition test) induced by diabetic neuropathic pain in rats. (a) Intraperitoneal injection of PZ-1386 (25 µmol/kg) but not PZ-1179 (25 µmol/kg), or vehicle (Veh, water for injections), and (b) intrathecal injection of Tat-VEPE (300 ng/rat), improves novelty discrimination in STZ diabetic (STZ-D) rats (n = 7-16/group). \* p < 0.05, \*\* p < 0.01, vs. STZ-D Vehicle group, 1-way ANOVA.
4. Discussion

In the present study, we explored the effect of 5-HT<sub>6</sub> receptor inverse agonists and the potential role of mTOR in painful diabetic neuropathy. After diabetes, we found that mechanical hypersensitivity and co-morbid cognitive deficits were alleviated with inverse agonists but not with neutral antagonists, suggesting that the constitutive activity of the 5-HT<sub>6</sub> receptor plays a critical role in the development of diabetic neuropathic pain. More importantly, while rapamycin suppressed diabetic-induced mechanical hyperalgesia, disrupting the interaction between spinal 5-HT<sub>6</sub> receptors and mTOR that physically interacts with their C-terminal ending could also ameliorate mechanical hyperalgesia induced by diabetic neuropathic pain. In addition, the novel inverse agonists also suppressed tactile hypersensitivity to von Frey hair application in models of traumatic and toxic neuropathic pain.

The experimental model of STZ-induced diabetic rats is a reliable model of diabetic neuropathic pain with a high translational value [25,42–44]. To reduce mortality due to STZ acute toxicity, young rats aged 6 weeks were chosen at the time of STZ injection as previously preconized [45]. Furthermore, in order to prevent decreasing health status confounding behavioral readouts, STZ rats with confirmed hyperglycemia were treated with insulin every other day, and pharmacological experiments were performed 21 days post-STZ treatment as recommended [46].

PZ-1388 and its two derivatives, PZ-1386 and PZ-1179, are selective 5-HT<sub>6</sub> receptor ligands characterized as inverse agonists [21–23]. The 5-HT<sub>6</sub> receptor is a G protein-coupled receptor that exhibits constitutive activity in vivo [20], including in a preclinical model of traumatic neuropathy [21]. Constitutive activity of 5-HT<sub>6</sub> receptors has been previously shown to be responsible for enhanced mTOR activity in the spinal cord of SNL and OXA rats and remains to be explored in the context of painful diabetic neuropathy. In the present study, we provide evidence of the involvement of 5-HT<sub>6</sub> receptor constitutive activity in the animal model of STZ-induced diabetic rats. The effects of the 5-HT<sub>6</sub> inverse agonists in diabetic rats were assessed on a painful symptom induced by sustained and increasing paw pressure, a procedure able to reveal mechanical hyperalgesia in 79% of diabetic rats. PZ-1388 and its two derivatives, PZ-1179 and PZ-1386, display similar antihyperalgesic effects with high efficacy, leading to an improvement in the pain of 60 to 109% and a relatively long duration of effect, at least 180 min, for all the molecules tested at a dose of 25 µmol/kg.

Despite having different pharmacokinetic parameters for 2-phenyl-1H-pyrrole-3-carboxamide-derived 5-HT<sub>6</sub> receptor inverse agonists, such as the brain-plasma ratio (4.44, 2.18, 0.64 for PZ-1388, PZ-1386, and PZ-1179, respectively), time to maximal brain concentration (Tmax value of 5 min for PZ-1179, 30 min for PZ-1388 and PZ-1386) and brain half-life (T<sub>1/2</sub> value of 250.9 min for PZ-1179, 414.7 min for PZ-1388, and 1743 min for PZ-1386) [21–23], the antihyperalgesic effect of the 5-HT<sub>6</sub> inverse agonists in diabetic rats was of similar magnitude and duration. Nevertheless, the brain Cmax values reported for PZ-1388 (1877 nM), PZ-1386 (876 nM), and PZ-1179 (882 nM) in rats receiving 10 mg/kg each (p. o.) were all much higher than the IC<sub>50</sub> values at Gs signaling (164 nM, 164 nM, and 265 nM, for PZ-1388, PZ-1386, and PZ-1179, respectively). This suggests that at the dose of 25 µmol/kg (12.5 mg/kg), the theoretical brain Cmax values are 4 (PZ-1179), 6 (PZ-1386), and 14 (PZ-1388) times that of the IC<sub>50</sub> at Gs signaling, explaining the absence of difference in the maximum magnitude of the antihyperalgesic activity. More interestingly, the dose of 5 µmol/kg may correspond to theoretical brain Cmax values 2.9, 1.34, and 0.83 times that of the IC<sub>50</sub> values for PZ-1388, PZ-1386, and PZ-1179, respectively. This suggests that the overall activity measured by A.U.C. of PZ-1388 should be higher than that of PZ-1386 and PZ-1179. Despite an apparent overall effect (A.U.C.) greater for PZ-1388 than PZ-1386 and PZ-1179 (Figure 1e) there is no significant difference (Table 1), suggesting that the paw pressure test is probably not sensitive enough to reveal such a difference.

The effect currently observed with SB258585 on mechanical hyperalgesia appears sim-
ilar in duration to those previously reported on tactile allodynia in SNL and OXA rats [21].
Intraperitoneal administration of SB258585 has been reported to reduce thermal hyperalgesia in STZ diabetic mice and to be effective for 120 min after injection [47]. The compound has also been shown to reverse formalin-induced secondary hyperalgesia in rats [48] and to decrease tactile allodynia in SNL rats [49].

Finally, the antihyperalgesic effect of 5-HT<sub>6</sub> receptor inverse agonists is comparable to that reported in diabetic rats with pregabalin, one of the reference treatments in neuropathic pain, but it occurs at a lower dose (equivalent to 12.5 mg/kg) than the pregabalin dose (30 mg/kg, p. o.) [50]. Overall, these experimental observations are much more satisfactory than those reported in clinical trials, with first-line treatments offering, at best, only partial relief of neuropathic pain for one patient out of three (NNT = 3) [12,51].

Remarkably, the analgesic effect of the inverse agonists observed in diabetic neuropathy was also observed in neuropathy of traumatic and toxic etiologies on tactile hypersensitivity in response to von Frey filaments application. The von Frey hair test is a relevant method to explore neuropathic pain in SNL and OXA rats since 70–80% of the animals present a reduction in paw withdrawal threshold compared to only 50% of STZ diabetic rats (personal data). Time follow-up of the effect of PZ-1179 shows that its anti-allodynic activity was much greater in SNL and OXA rats than its anti-hyperalgesic effect in STZ diabetic rats, leading to a threshold higher than that measured before the induction of neuropathy. The effect of PZ-1386 also seems to depend on the etiology of neuropathy; it induced a more marked anti-allodynic effect on tactile allodynia in OXA rats than previously reported in SNL rats [22]. Importantly, the lack of antinociceptive effect of both inverse agonists in healthy conditions further supports that 5-HT<sub>6</sub> receptor inhibition specifically alleviates painful symptoms characteristic of neuropathic pain.

Antagonizing spinal 5-HT<sub>6</sub> receptors with a neutral antagonist did not affect mechanical hyperalgesia or tactile hypersensitivity but suppressed inverse agonist-induced analgesia. This result indicates and confirms that mechanical hyperalgesia and tactile hypersensitivity induced by diabetic, traumatic, and toxic neuropathy depend on the constitutive activity of the 5-HT<sub>6</sub> receptor rather than its activation by endogenously released serotonin. Consistent with previous data obtained in SNL rats, the suppression of the analgesic effect after intrathecal administration of the antagonist also indicated that spinally located 5-HT<sub>6</sub> receptors are involved in this effect. This is supported by the presence of 5-HT<sub>6</sub> receptors in the dorsal spinal cord [21], expressed in excitatory interneurons receiving signals from low threshold mechanoreceptors [15].

We do not provide direct evidence of the attenuation of 5-HT<sub>6</sub> receptor-dependent mTOR activity by inverse agonists. Nevertheless, both (i) the *in vitro* western blot analysis of the phosphorylation of mTOR and a downstream protein, S6, showing a decreased expression after 5-HT<sub>6</sub> receptor inverse agonists application and (ii) the behavioral experiment conducted with intrathecal administration of the peptide Tat-VEPE designed to disrupt 5-HT<sub>6</sub> receptor-mTOR interaction, indicate that mTOR, under the dependence of the 5-HT<sub>6</sub> receptor, is likely involved in diabetic neuropathy-induced mechanical hyperalgesia. Indeed, Tat-VEPE reduced mechanical hyperalgesia leading to a 68% improvement in pain. The dose-dependent effect of rapamycin appeared more marked than that of Tat-VEPE peptide (maximal effect corresponding to the total suppression of allodynia). As mTOR is a ubiquitous signaling protein, the effects observed after intrathecal injection of rapamycin are suggestive of broader effects of rapamycin in the central nervous system (CNS) (other than those dependent on the 5-HT<sub>6</sub> receptor) and, in particular, effects targeting mTOR activation elicited by APPLI deficiency, a mechanism that has been shown in the dorsal horn of the spinal cord of hyperalgesic diabetic rats [52]. Taken together, these data provide evidence that the 5-HT<sub>6</sub> receptor-dependent mTOR signaling pathway contributes to mechanical hyperalgesia in diabetic rats.

Although PZ-1179 has been shown to prevent scopolamine-induced cognitive deficits in the NOR test in rats [23] and is analgesic in the present study, it failed to improve episodic memory in STZ diabetic rats. This discrepancy may be due to the lower CNS penetrance and shorter brain T<sub>1/2</sub> of PZ-1179 compared to PZ-1386. Further administration modalities
need to be performed to support this hypothesis. Finally, consistent with recent findings showing the pro-cognitive effect of SB258585 and PZ-1388 in SNL rats [21], intraperitoneal administration of PZ-1386 and intrathecal injection of Tat-VEPE improved co-morbid cognitive deficits in diabetic rats, a highly prevalent complication of diabetes [9].

Taken together, these data suggest that 5-HT<sub>6</sub> receptor inverse agonists—already in clinical development for the treatment of cognitive impairment in dementia and psychoses—and strategies disrupting 5-HT<sub>6</sub> receptor-mTOR interaction, might be new therapeutic approaches for the treatment of diabetic neuropathic pain, in addition to neuropathic pain of traumatic and toxic etiologies.

**5. Conclusions**

The present study demonstrated that the constitutive activity of the 5-HT<sub>6</sub> receptor in the dorsal horn of the spinal cord plays a critical role in the pathophysiology of diabetic neuropathic pain via dependent activation of mTOR signaling, suggesting a potential therapeutic interest in targeting constitutively active 5-HT<sub>6</sub> receptors or 5-HT<sub>6</sub> receptor-mTOR complexes for the treatment of neuropathic pain and cognitive co-morbidities.

**Supplementary Materials:** The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/biom13020364/s1, Figure S1: Inverse agonists reduce 5-HT6 receptors constitutive activity at mTOR signaling.; Figure S2: Effect of 5-HT6 receptor inverse agonists on tactile hypersensitivity (von Frey hair test) in OXA and SNL rats; Figure S3: Effect of 5-HT6 receptor inverse agonists on mechanical nociception in healthy control rats; Table S1: Detailed statistics for Figures S1 and S2.

**Author Contributions:** Conceptualization, P.Z., P.M., S.D. and C.C.; methodology, F.L., S.D. and C.C.; formal analysis, N.M., S.D. and C.C.; investigation, N.M., M.D., F.J., S.L., E.C., L.P., Y.A., V.C. and S.D.; resources, C.C.; data curation, C.C.; writing—original draft preparation, N.M., S.D. and C.C.; writing—review and editing, N.M., S.D., P.Z., P.M. and C.C.; supervision, S.D. and C.C.; project administration, C.C.; funding acquisition, P.M. and C.C. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research was funded by the Agence Nationale de la Recherche (ANR) (N° ANR-19-CE18-0018-01 and "Investissements d'Avenir" ANR-16-IDEX-0001 CAP 20-25), the Institut National de la Santé et de la Recherche Médicale (INSERM), the Centre National de la Recherche Scientifique (CNRS), the Auvergne-Rhône-Alpes Région (France), the Université Clermont Auvergne, the Université de Montpellier and the National Science Centre, Poland (grant no. 2016/21/B/NZ7/01742). N.M. received a scholarship from the french Ministère de l'Enseignement Supérieur, de la Recherche et de l'Innovation (MESRI).

**Institutional Review Board Statement:** The animal study protocols were approved by the local Comité d'Ethique en Matière d'Expérimentation Animale CEMEA Auvergne (registration code CEEA-002) and by the French Ministère de l'Enseignement Supérieur, de la Recherche et de l'Innovation (protocol n° 5175 approved on 11/29/2017; protocol n° 17573 approved on 11/25/2019 and protocol n° 24498 approved on 01/18/2019).

**Informed Consent Statement:** Not applicable.

**Data Availability Statement:** All data supporting reported results in this article can be obtained from the corresponding author on request.

**Acknowledgments:** The authors thank the technical support from personnel from the animal facility at the UCA.

**Conflicts of Interest:** The authors declare no conflict of interest.

**References**

1. *IDF Diabetes Atlas*, 10th ed.; International Diabetes Federation: Brussels, Belgium, 2021.

2. Chong, M.S.; Hester, J. Diabetic Painful Neuropathy: Current and Future Treatment Options. *Drugs* **2007**, *67*, 569–585. [CrossRef] [PubMed]
3. Holt, R.I.G. (Ed.) *Textbook of Diabetes*, 4th ed.; Wiley-Blackwell: Chichester, West Sussex, UK; Hoboken, NJ, USA, 2010; ISBN 978-1-4051-9181-4.

4. Jensen, T.S.; Baron, R.; Haanpaa, M.; Kalso, E.; Loeser, J.D.; Rice, A.S.; Treede, R.D. A New Definition of Neuropathic Pain. *Pain* **2011**, *152*, 2204–2205. [CrossRef] [PubMed]

5. Tesfaye, S.; Boulton, A.J.M.; Dyck, P.J.; Freeman, R.; Horowitz, M.; Kempler, P.; Lauria, G.; Malik, R.A.; Spallone, V.; Vinik, A.; et al. Diabetic Neuropathies: Update on Definitions, Diagnostic Criteria, Estimation of Severity, and Treatments. *Diabetes Care* **2010**, *33*, 2285–2293. [CrossRef]

6. Bouhassira, D.; Letanoux, M.; Hartemann, A. Chronic Pain with Neuropathic Characteristics in Diabetic Patients: A French Cross-Sectional Study. *PLoS ONE* **2013**, *8*, e74195. [CrossRef] [PubMed]

7. Bai, J.-W.; Lovblom, L.E.; Cardinez, M.; Weisman, A.; Farooqi, M.A.; Halpern, E.M.; Boulet, G.; Eldelekli, D.; Lovshin, J.A.; Lytvyn, Y.; et al. Neuropathy and Presence of Emotional Distress and Depression in Longstanding Diabetes: Results from the Canadian Study of Longevity in Type 1 Diabetes. *J. Diabetes Complicat.* **2017**, *31*, 1318–1324. [CrossRef]

8. Jain, A.; Sharmab, R.; Yadavc, N.; Chaudhary, P.; Jainc, G.; Maanju, M. Quality of Life and Its Association with Insomnia and Clinical Variables in Type 2 Diabetes. *J. Egypt Public Health Assoc.* **2017**, *92*, 52–59. [CrossRef]

9. Moheet, A.; Mangia, S.; Sequist, E.R. Impact of Diabetes on Cognitive Function and Brain Structure. *Ann. N. Y. Acad. Sci.* **2015**, *1353*, 60–71. [CrossRef]

10. Galer, B.S.; Gianas, A.; Jensen, M.P. Painful Diabetic Polyneuropathy: Epidemiology, Pain Description, and Quality of Life. *Diabetes Res. Clin. Pract.* **2000**, *47*, 123–128. [CrossRef]

11. Geelen, C.C.; Smeets, R.J.E.M.; Schmitz, S.; van den Bergh, J.P.; Goossens, M.E.J.B.; Verbunt, J.A. Anxiety Affects Disability and Quality of Life in Patients with Painful Diabetic Neuropathy. *Eur. J. Pain* **2017**, *21*, 1632–1641. [CrossRef]

12. Finnerup, N.B.; Attal, N.; Haroutounian, S.; McNicol, E.; Baron, R.; Dworkin, R.H.; Gilron, I.; Haanpaa, M.; Hansson, P.; Jensen, T.S.; et al. Pharmacotherapy for Neuropathic Pain in Adults: A Systematic Review and Meta-Analysis. *Lancet Neurol.* **2015**, *14*, 162–173. [CrossRef]

13. Tesfaye, S.; Sloan, G.; Petrie, J.; White, D.; Bradburn, M.; Julious, S.; Rajbhandari, S.; Sharma, S.; Rayman, G.; Gouni, R.; et al. Comparison of Amitriptyline Supplemented with Pregabalin, Pregabalin Supplemented with Amitriptyline, and Duloxetine Supplemented with Pregabalin for the Treatment of Diabetic Peripheral Neuropathic Pain (OPTION-DM): A Multicentre, Double-Blind, Randomised Crossover Trial. *Lancet* **2022**, *400*, 680–690. [CrossRef] [PubMed]

14. Rosenberger, D.C.; Blechschmidt, V.; Timmerman, H.; Wolff, A.; Treede, R.-D. Challenges of Neuropathic Pain: Focus on Diabetic Neuropathy. *J. Neural. Transm.* **2020**, *127*, 589–624. [CrossRef] [PubMed]

15. Abraira, V.E.; Kuehn, E.D.; Chirila, A.M.; Springel, M.W.; Toliver, A.A.; Zimmerman, A.L.; Orefice, L.L.; Boyle, K.A.; Bai, L.; Song, B.J.; et al. The Cellular and Synaptic Architecture of the Mechanosensory Dorsal Horn. *Cell* **2017**, *168*, 295–310.e19. [CrossRef]

16. Meffre, J.; Chaumont-Dubel, S.; Mannoury la Cour, C.; Loiseau, F.; Watson, D.J.; Dekeyne, A.; Seveno, M.; Rivet, J.M.; Gaven, F.; Deleris, P.; et al. 5-HT(6) Receptor Recruitment of MTOR as a Mechanism for Perturbed Cognition in Schizophrenia. *EMBO Mol. Med.* **2012**, *4*, 1043–1056. [CrossRef]

17. Duhr, F.; Déléris, P.; Raynaud, F.; Séveno, M.; Morisset-Lopez, S.; Mannoury la Cour, C.; Millan, M.J.; Bockaert, J.; Marin, P.; Chaumont-Dubel, S. Cdk5 Induces Constitutive Activation of 5-HT6 Receptors to Promote Neurite Growth. *Nat. Chem. Biol.* **2014**, *10*, 590–597. [CrossRef] [PubMed]

18. De Deurwaerdère, P.; Bharatiya, R.; Chagraoui, A.; Di Giovanni, G. Constitutive Activity of 5-HT Receptors: Factual Analysis. *Neuropharmacology* **2020**, *168*, 107967. [CrossRef]

19. Kohen, R.; Fashingbauer, L.A.; Heidmann, D.E.A.; Guthrie, C.R.; Hamblin, M.W. Cloning of the Mouse 5-HT6 Serotonin Receptor and Mutagenesis Studies of the Third Cytoplasmic Loop. *Mol. Brain Res.* **2001**, *90*, 110–117. [CrossRef]

20. Deraredj Nadim, W.; Chaumont-Dubel, S.; Madouri, F.; Cobret, L.; De Tauzia, M.-L.; Zajdel, P.; Bénédetti, H.; Marin, P.; Morisset-Lopez, S. Physical Interaction between Neurofibromin and Serotonin 5-HT<sub>6</sub> Receptor Promotes Receptor Constitutive Activity. *Proc. Natl. Acad. Sci. USA* **2016**, *113*, 12310–12315. [CrossRef]

21. Martin, P-Y.; Doly, S.; Hamieh, A.M.; Chapuy, E.; Canale, V.; Drop, M.; Chaumont-Dubel, S.; Bantreil, X.; Lamaty, F.; Bojarski, A.J.; et al. MTOR Activation by Constitutively Active Serotonin<sub>6</sub> Receptors as New Paradigm in Neuropathic Pain and Its Treatment. *Prog. Neurobiol.* **2020**, *193*, 101846. [CrossRef]

22. Drop, M.; Jacquot, F.; Canale, V.; Chaumont-Dubel, S.; Walczak, M.; Satała, G.; Nosalska, K.; Mahoro, G.U.; Słoczyńska, K.; Piska, K.; et al. Neuropathic Pain-Alleviating Activity of Novel 5-HT<sub>6</sub> Receptor Inverse Agonists Derived from 2-Aryl-1H-Pyrrole-3-Carboxamide. *Bioorganic Chem.* **2021**, *115*, 105218. [CrossRef]

23. Drop, M.; Canale, V.; Chaumont-Dubel, S.; Kurczab, R.; Satała, G.; Bantreil, X.; Walczak, M.; Koczurkiewicz-Adamczyk, P.; Latacz, G.; Gwizdak, A.; et al. 2-Phenyl-1 *H* -Pyrrole-3-Carboxamide as a New Scaffold for Developing 5-HT<sub>6</sub> Receptor Inverse Agonists with Cognition-Enhancing Activity. *ACS Chem. Neurosci.* **2021**, *12*, 1228–1240. [CrossRef] [PubMed]

24. Saxton, R.A.; Sabatini, D.M. MTOR Signaling in Growth, Metabolism, and Disease. *Cell* **2017**, *168*, 960–976. [CrossRef] [PubMed]

25. Courteix, C.; Bardin, M.; Chantelauze, C.; Lavarenne, J.; Eschalier, A. Study of the Sensitivity of the Diabetes-Induced Pain Model in Rats to a Range of Analgesics. *Pain* **1994**, *57*, 153–160. [CrossRef] [PubMed]

26. Courteix, C.; Eschalier, A.; Lavarenne, J. Streptozocin-Induced Diabetic Rats: Behavioural Evidence for a Model of Chronic Pain. *Pain* **1993**, *53*, 81–88. [CrossRef] [PubMed]
27. Rafiey, M.; Nosrati, R.; Babaei, P. Protective Effect of MiR-34c Antagomir against STZ-Induced Memory Impairment by Targeting MTOR and PSD-95 in the Hippocampus of Rats. *Neurosci. Lett.* **2022**, *789*, 136881. [CrossRef]

28. He, W.-Y.; Zhang, B.; Zhao, W.-C.; He, J.; Wang, Y.; Zhang, L.; Xiong, Q.-M.; Wang, H.-B. MTOR Activation Due to APPI1 Deficiency Exacerbates Hyperalgesia via Rab5/Akt and AMPK Signaling Pathway in Streptozocin-Induced Diabetic Rats. *Mol. Pain* **2019**, *15*, 174480691988064. [CrossRef]

29. Inyang, K.E.; Szabo-Pardi, T.; Wentworth, E.; McDougal, T.A.; Dussor, G.; Burton, M.D.; Price, T.J. The Antidiabetic Drug Metformin Prevents and Reverses Neuropathic Pain and Spinal Cord Microglial Activation in Male but Not Female Mice. *Pharmacol. Res.* **2019**, *139*, 1–16. [CrossRef]

30. Cao, X.-J.; Wu, R.; Qian, H.-Y.; Chen, X.; Zhu, H.-Y.; Xu, G.-Y.; Sun, Y.-Z.; Zhang, P.-A. Metformin Attenuates Diabetic Neuropathic Pain via AMPK/NF-KB Signaling Pathway in Dorsal Root Ganglion of Diabetic Rats. *Brain Res.* **2021**, *1772*, 147663. [CrossRef]

31. Kilkenny, C.; Browne, W.; Cuthill, I.C.; Emerson, M.; Altman, D.G. Animal Research: Reporting in Vivo Experiments: The ARRIVE Guidelines. *Br. J. Pharmacol.* **2010**, *160*, 1577–1579. [CrossRef]

32. Kim, S.H.; Chung, J.M. An Experimental Model for Peripheral Neuropathy Produced by Segmental Spinal Nerve Ligation in the Rat. *Pain* **1992**, *50*, 355–363. [CrossRef]

33. Ling, B.; Authier, N.; Balayssac, D.; Eschalier, A.; Coudore, F. Behavioral and Pharmacological Description of Oxaliplatin-Induced Painful Neuropathy in Rat. *Pain* **2007**, *128*, 225–234. [CrossRef]

34. Randall, L.O.; Selitto, J.J. A Method for Measurement of Analgesic Activity on Inflamed Tissue. *Arch. Int. Pharm. Therm.* **1957**, *111*, 409–419.

35. Chaplan, S.R.; Bach, F.W.; Pogrel, J.W.; Chung, J.M.; Yaksh, T.L. Quantitative Assessment of Tactile Allodynia in the Rat Paw. *J. Neurosci.* Methods **1994**, *53*, 55–63. [CrossRef]

36. Dixon, W.J. Efficient Analysis of Experimental Observations. *Annu. Rev. Pharmacol. Toxicol.* **1980**, *20*, 441–462. [CrossRef]

37. Ennaceur, A.; Delacour, J. A New One-Trial Test for Neurobiological Studies of Memory in Rats. 1: Behavioral Data. *Behav. Brain Res.* **1988**, *31*, 47–59. [CrossRef]

38. Grychowska, K.; Satała, G.; Kos, T.; Partyka, A.; Colacino, E.; Chaumont-Dubel, S.; Bantreil, X.; Wesołowska, A.; Pawłowski, M.; Martinez, J.; et al. Novel 1 *H*-Pyrrolo[3,2-*c*]Quinoline Based 5-*HT* 6 Receptor Antagonists with Potential Application for the Treatment of Cognitive Disorders Associated with Alzheimer's Disease. *ACS Chem. Neurosci.* **2016**, *7*, 972–983. [CrossRef]

39. Rondón, L.J.; Farges, M.C.; Davin, N.; Sion, B.; Privat, A.M.; Vasson, M.P.; Eschalier, A.; Courteix, C. L-Arginine Supplementation Prevents Allodynia and Hyperalgesia in Painful Diabetic Neuropathic Rats by Normalizing Plasma Nitric Oxide Concentration and Increasing Plasma Agmatine Concentration. *Eur. J. Nutr.* **2018**, *57*, 2353–2363. [CrossRef]

40. Vanda, D.; Canale, V.; Chaumont-Dubel, S.; Kurczab, R.; Satała, G.; Koczurkiewicz-Adamczyk, P.; Krawczyk, M.; Pietruś, W.; Blicharz, K.; Pękala, E.; et al. Imidazopyridine-Based 5-*HT* 6 Receptor Neutral Antagonists: Impact of *N* 1 -Benzyl and *N* 1 -Phenylsulfonyl Fragments on Different Receptor Conformational States. *J. Med. Chem.* **2021**, *64*, 1180–1196. [CrossRef]

41. Zajdel, P.; Marciniec, K.; Satała, G.; Canale, V.; Kos, T.; Partyka, A.; Jastrzębska-Więsek, M.; Wesołowska, A.; Basińska-Ziobroń, A.; Wójcikowski, J.; et al. *N* 1-Azinylsulfonyl-1 *H*-Indoles: 5-*HT*6 Receptor Antagonists with Procognitive and Antidepressant-Like Properties. *ACS Med. Chem. Lett.* **2016**, *7*, 618–622. [CrossRef]

42. Courteix, C.; Eschalier, A.; Mallet, C. L'évaluation de La Douleur Chez l'animal de Laboratoire. *Douleur Analg.* **2021**, *34*, 114–122. [CrossRef]

43. Wattiez, A.-S.; Dupuis, A.; Courteix, C. Le rat STZ-diabétique: Modèle adapté à l'étude de la neuropathie diabétique douloureuse? *Douleur Analg.* **2012**, *25*, 38–45. [CrossRef]

44. Wattiez, A.-S.; Barrière, D.A. Rodent Models of Painful Diabetic Neuropathy: What Can We Learn from Them? *J. Diabetes Metab.* **2012**, *S5*, 008. [CrossRef]

45. Wang-Fischer, Y.; Garyantes, T. Improving the Reliability and Utility of Streptozotocin-Induced Rat Diabetic Model. *J. Diabetes Res.* **2018**, *2018*, 8054073. [CrossRef]

46. Handwerker, H.O.; Arendt-Nielsen, L. (Eds.) *Pain Models: Translational Relevance and Applications*; IASP Press: Washington, DC, USA, 2013; ISBN 978-0-931092-94-7.

47. Sari, C.C.; Gunduz, O.; Ulugol, A. Spinal Serotonin and 5HT6 Receptor Levels During Development of Neuropathy and Influence of Blockade of These Receptors on Thermal Hyperalgesia in Diabetic Mice. *Drug Res.* **2019**, *69*, 428–433. [CrossRef]

48. Godinez-Chaparro, B.; Lopez-Santillan, F.J.; Orduna, P.; Granados-Soto, V. Secondary Mechanical Allodynia and Hyperalgesia Depend on Descending Facilitation Mediated by Spinal 5-HT(4), 5-HT(6) and 5-HT(7) Receptors. *Neuroscience* **2012**, *222*, 379–391. [CrossRef]

49. Pineda-Farias, J.B.; Barragán-Iglesias, P.; Valdivieso-Sánchez, A.; Rodríguez-Silverio, J.; Flores-Murrieta, F.J.; Granados-Soto, V.; Rocha-González, H.I. Spinal 5-HT 4 and 5-HT 6 Receptors Contribute to the Maintenance of Neuropathic Pain in Rats. *Pharmacol. Rep.* **2017**, *69*, 916–923. [CrossRef]

50. Yamamoto, H.; Shimoshige, Y.; Yamaji, T.; Murai, N.; Aoki, T.; Matsuoka, N. Pharmacological Characterization of Standard Analgesics on Mechanical Allodynia in Streptozotocin-Induced Diabetic Rats. *Neuropharmacology* **2009**, *57*, 403–408. [CrossRef]
51. Finnerup, N.B.; Haroutounian, S.; Baron, R.; Dworkin, R.H.; Gilron, I.; Haanpaa, M.; Jensen, T.S.; Kamerman, P.R.; McNicol, E.; Moore, A.; et al. Neuropathic Pain Clinical Trials: Factors Associated with Decreases in Estimated Drug Efficacy. *Pain* **2018**, *159*, 2339–2346. [CrossRef]

52. He, W.; Zhang, B.; Zhao, W.; He, J.; Zhang, L.; Xiong, Q.; Wang, J.; Wang, H. Contributions of MTOR Activation-Mediated Upregulation of Synapsin II and Neurite Outgrowth to Hyperalgesia in STZ-Induced Diabetic Rats. *ACS Chem. Neurosci.* **2019**, *10*, 2385–2396. [CrossRef]

**Disclaimer/Publisher's Note:** The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.